Etomidate Injection Shortage: Current FDA Status
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Etomidate Injection is listed in the FDA Drug Shortage Database with a current status, but it remains available from all manufacturers as of the latest update.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 7, 2026 and geographically references United States. Its severity classification of "low" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Etomidate Injection.
What's in Shortage
The drug in shortage is Etomidate Injection, with the generic name Etomidate Injection. Brand names include AMIDATE and ETOMIDATE. It is available in the dosage form of Injection and falls under the therapeutic category of Anesthesia. The current status is Current, with the shortage first posted on 10/05/2022 and last updated on 03/27/2026.
Which Manufacturers Are Affected
- Hospira, Inc., a Pfizer Company: Available, with presentation Amidate, Injection, 2 mg/mL (NDC 0409-6695-02), and contact information 844-646-4398.
- Mylan Institutional, a Viatris Company: Available, with presentation Etomidate, Injection, 2 mg/1 mL (NDC 67457-902-10), and contact information 800-796-9526.
- Mylan Institutional, a Viatris Company: Available, with presentation Etomidate, Injection, 2 mg/1 mL (NDC 67457-903-20), and contact information 800-796-9526.
- Hospira, Inc., a Pfizer Company: Available, with presentation Amidate, Injection, 2 mg/1 mL (NDC 0409-6695-01), and contact information 844-646-4398.
Why There's a Shortage
No specific reason was provided for this listing in the source data.
What Patients Should Do
If you rely on Etomidate Injection, consider discussing availability with your pharmacist or healthcare provider. You may also contact the manufacturers directly using the provided numbers. Please remember that patients should always consult their healthcare provider for any medical advice or concerns, and do not make changes to your treatment without professional guidance.
Source
This information is attributed to the FDA Drug Shortage Database, initially posted on 10/05/2022 and last updated on 03/27/2026.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA drug-shortage notice: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,671 characters here).
Similar severity timing
Same severity (low) notices issued closest in time to April 7, 2026.
Frequently Asked Questions
Common questions about this FDA drug-shortage notice.